Researchers report cabamiquine effective with pyronaridine in early trials
Researchers at the University of Dundee discovered cabamiquine, a novel drug-like molecule that can be given as a single dose and may simplify malaria prevention and treatment. Early-stage trials conducted by Merck under the PAMAfrica consortium found cabamiquine combined with existing drug pyronaridine was effective and had a favourable safety profile in adults and teenagers. The Lancet Infectious Diseases published the findings, and Medicines for Malaria Venture plans to advance the combined therapy into larger trials and paediatric testing amid rising resistance and a 2024 global malaria burden of 282 million cases and 610,000 deaths.
Cabamiquine with pyronaridine showed effective single-dose results.
Context
Malaria cases and deaths have risen partly because current drugs face rising resistance. Researchers discovered cabamiquine and early trials with pyronaridine showed positive results. Next, groups plan larger trials and tests in children.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked